127 related articles for article (PubMed ID: 23721228)
1. Barriers to participation in actual HIV vaccine trials.
Dhalla S; Poole G
Curr HIV Res; 2013 Apr; 11(3):238-45. PubMed ID: 23721228
[TBL] [Abstract][Full Text] [Related]
2. Barriers to Participation in Actual HIV Vaccine Trials.
Dhalla S; Poole G
Curr HIV Res; 2013 Feb; ():. PubMed ID: 23432421
[TBL] [Abstract][Full Text] [Related]
3. Motivators to participation in actual HIV vaccine trials.
Dhalla S; Poole G
AIDS Behav; 2014 Feb; 18(2):263-77. PubMed ID: 23736885
[TBL] [Abstract][Full Text] [Related]
4. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.
Dhalla S; Poole G
Vaccine; 2011 Aug; 29(35):5850-9. PubMed ID: 21740947
[TBL] [Abstract][Full Text] [Related]
5. An update on human immunodeficiency virus vaccine preparedness studies.
Dhalla S
J Med Microbiol; 2015 Jul; 64(7):731-738. PubMed ID: 25908608
[TBL] [Abstract][Full Text] [Related]
6. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.
Dhalla S; Poole G
AIDS Care; 2011 Nov; 23(11):1430-47. PubMed ID: 21722022
[TBL] [Abstract][Full Text] [Related]
7. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.
Jenkins RA; Chinaworapong S; Morgan PA; Ruangyuttikarn C; Sontirat A; Chiu J; Michael RA; Nitayaphan S; Khamboonruang C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):171-7. PubMed ID: 9637582
[TBL] [Abstract][Full Text] [Related]
8. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
[TBL] [Abstract][Full Text] [Related]
9. Predicting hypothetical willingness to participate (WTP) in a future phase III HIV vaccine trial among high-risk adolescents.
Giocos G; Kagee A; Swartz L
AIDS Behav; 2008 Nov; 12(6):842-51. PubMed ID: 17668313
[TBL] [Abstract][Full Text] [Related]
10. Willingness to participate in HIV vaccine clinical trials among Chinese men who have sex with men.
Li Q; Luo F; Zhou Z; Li S; Liu Y; Li D; Shi W; Raymond HF; Ruan Y; Shao Y
Vaccine; 2010 Jun; 28(29):4638-43. PubMed ID: 20452428
[TBL] [Abstract][Full Text] [Related]
11. Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection.
Voytek CD; Jones KT; Metzger DS
Vaccine; 2011 Aug; 29(36):6130-5. PubMed ID: 21704110
[TBL] [Abstract][Full Text] [Related]
12. Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention.
Dhalla S; Poole G
Hum Vaccin Immunother; 2014; 10(7):1974-84. PubMed ID: 25424807
[TBL] [Abstract][Full Text] [Related]
13. Response to Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial.
Halpern SD
J Acquir Immune Defic Syndr; 2003 Jul; 33(3):412. PubMed ID: 12843757
[No Abstract] [Full Text] [Related]
14. HIV vaccine preparedness studies in the non-organization for economic co-operation and development (non-OECD) countries.
Dhalla S; Nelson KE; Singer J; Poole G
AIDS Care; 2009 Mar; 21(3):335-48. PubMed ID: 18781449
[TBL] [Abstract][Full Text] [Related]
15. Socioeconomic status and HIV vaccine preparedness studies in North America.
Dhalla S; Poole G
Vaccine; 2015 May; 33(22):2536-45. PubMed ID: 25820065
[TBL] [Abstract][Full Text] [Related]
16. Willingness to participate in South African HIV vaccine trials--concerns of medical professionals in the Western Cape.
Moodley K; Barnes J; van Rensburg EJ; Myer L
S Afr Med J; 2002 Nov; 92(11):904-6. PubMed ID: 12506594
[TBL] [Abstract][Full Text] [Related]
17. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note.
Chesney MA; Chambers DB; Kahn JO
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Dec; 16(4):266-71. PubMed ID: 9402073
[TBL] [Abstract][Full Text] [Related]
18. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein.
Luzi AM; Gallo P; Colucci A; Marcotullio S; Bellino S; Longo O; Ensoli B
AIDS Care; 2011 Aug; 23(8):939-46. PubMed ID: 21390884
[TBL] [Abstract][Full Text] [Related]
19. Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials.
Doshi M; Avery L; Kaddu RP; Gichuhi M; Gakii G; du Plessis E; Dutta S; Khan S; Kimani J; Lorway RR
BMC Public Health; 2017 May; 17(1):469. PubMed ID: 28521748
[TBL] [Abstract][Full Text] [Related]
20. Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users.
Golub ET; Purvis LA; Sapun M; Safaeian M; Beyrer C; Vlahov D; Strathdee SA
AIDS Behav; 2005 Sep; 9(3):301-9. PubMed ID: 16088366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
